Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

38.41 +0.73 (+1.95%)

Streaming Delayed Price Updated: 2:15 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Volume	406,744
Open	37.75
Bid (Size)	38.35 (100)
Ask (Size)	38.45 (300)
Prev. Close	37.68
Today's Range	37.54 - 38.93
52wk Range	12.91 - 42.13
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗

December 24, 2025

Two analysts waxed bullish on the future of the company.

Via The Motley Fool

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗

December 18, 2025

Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors.

Via Chartmill

Performance

YTD	+102.5%	+102.5%
1 Month	+9.2%	+9.2%
3 Month	+60.7%	+60.7%
6 Month	+161.1%	+161.1%
1 Year	+121.8%	+121.8%

More News

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 11, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗

November 27, 2025

Via Chartmill

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Via Investor's Business Daily

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

Via The Motley Fool

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

Via The Motley Fool

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025

November 06, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

Via MarketMinute

Travere Therapeutics to Participate at Upcoming Investor Conferences

November 04, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat ↗

October 31, 2025

Via Investor's Business Daily

Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments ↗

October 30, 2025

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 30, 2025

Via Benzinga

Travere Therapeutics Reports Third Quarter 2025 Financial Results

October 30, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Report Third Quarter 2025 Financial Results

October 23, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025

October 17, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Via Benzinga

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup ↗

October 16, 2025

Via Chartmill

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Travere Therapeutics, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

Via Benzinga

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

September 26, 2025

From Travere Therapeutics, Inc.

Via Business Wire

The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts ↗

September 19, 2025

Via Benzinga

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 11, 2025

From Travere Therapeutics, Inc.

Via Business Wire

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?

Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Travere Therapeutics, Inc. - Common Stock trade on?

Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?

The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market

What is the current price of Travere Therapeutics, Inc. - Common Stock?

The current price of Travere Therapeutics, Inc. - Common Stock is 38.41

When was Travere Therapeutics, Inc. - Common Stock last traded?

The last trade of Travere Therapeutics, Inc. - Common Stock was at 12/31/25 02:15 PM ET

What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?

The market capitalization of Travere Therapeutics, Inc. - Common Stock is 2.33B

How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?

Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.